Status:
RECRUITING
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
Lead Sponsor:
VelaVigo Bio Inc
Conditions:
Participants With Advanced Solid Tumor Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or...
Eligibility Criteria
Inclusion
- A participant must meet all of the following inclusion criteria to be eligible to participate in this trial:
- 1\. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
- 2\. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or for which no standard treatment is available
- 3\. At least one measurable lesion as assessed by the investigator according to RECIST v1.1criteria
- 4\. Male or female adults (defined as ≥ 18 years of age)
- 5\. ECOG performance status 0-1
- 6\. Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
- 7\. Life expectancy greater than 12 weeks
- 8\. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.
- 9\. Adequate organ and bone marrow function
- 10\. Participants must meet the minimum washout period requirements before the first dose of investigational drug
Exclusion
- 1\. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment, except for alopecia, neuropathy, or skin pigmentation changes. Participants with chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the study investigator and the Sponsor's Medical Monitor.
- 2\. Known or suspected brain metastases, or spinal cord compression, unless the condition has been treated, asymptomatic, and has been stable without requiring escalating doses of corticosteroids (equivalent to ≤10 mg/day prednisone) or anti-convulsant medications for at least four weeks prior for the first dose of investigational drug.
- 3\. Prior treatment with an ADC targeting EGFR and/or cMet (including VBC101)
- 4\. Prior treatment with any ADC carrying a TOP1i payload (including prior VBC101).
- 5\. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
Key Trial Info
Start Date :
September 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT07136779
Start Date
September 23 2025
End Date
July 1 2028
Last Update
October 24 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Start Midwest
Grand Rapids, Michigan, United States, 49546
2
NEXT Oncology
San Antonio, Texas, United States, 78229
3
START Mountain Region, LLC.
West Valley City, Utah, United States, 84119
4
NEXT Virginia
Fairfax, Virginia, United States, 22031